US5783215A - Pharmaceutical preparation - Google Patents
Pharmaceutical preparation Download PDFInfo
- Publication number
- US5783215A US5783215A US08/464,773 US46477395A US5783215A US 5783215 A US5783215 A US 5783215A US 46477395 A US46477395 A US 46477395A US 5783215 A US5783215 A US 5783215A
- Authority
- US
- United States
- Prior art keywords
- controlled release
- hydrophilic polymer
- pharmaceutical preparation
- active substance
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to controlled release beads and a novel pharmaceutical preparation containing a core around which is a drug-containing layer e.g. a layer containing an active substance, i.e. a practically insoluable active substance, preferably furosemid to the use of said preparation and to a process for preparing the same.
- a drug-containing layer e.g. a layer containing an active substance, i.e. a practically insoluable active substance, preferably furosemid to the use of said preparation and to a process for preparing the same.
- the present invention provides a novel a pharmaceutical multiple unit dose preparation with very favourable characteristics which may withstand mechanical stress, i.e. during compaction. These favourable mechanical characteristics are advantageous when dealing with multiple unit dose systems comprising modified or controlled release properties.
- a common problem with multiple unit dose systems designated to have modified or controlled release properties is their sensitivity to mechanical stress, e.g. compaction stress, giving rise to rupturing and cracking of the release controlling membrane (Bechard and Leroux 1992) or fragmentation of the core (Magnatiand Celik 1994).
- Multiple unit dosage systems may be filled into capsules or sachets, thus requiring sufficient mechanical properties to withstand processing. It may even be advantageous to compact multiple units into tablets, subjecting the systems to significant mechanical stress.
- inert and non-soluble cores of glass or sand particles or soluble cores such as sugar spheres capable of withstanding mechanical stress, in combination with a plasticizing layer of a hydrophilic polymer containing the active substance, optionally with additional layers of the polymer not containing the active substance, layered between the core and the release controlling membrane.
- films manufactured from an ethyl cellulose pseudolatex dispersion plasticized with 24% DBS, suitable for the controlled release of chlorpheniramine maleate from small pellets with a size of 250-840 mm, are described. These films do not, however, have the appropriate mechanical properties to withstand compaction forces without rupturing, and the controlled release properties of the compacted pellets are thus lost during the process.
- U.S. Pat. No. 4,713,248 describes a controlled release multiple unit formulation containing an active substance coated with a water based film comprising a homogeneous combination of water-dispersable film forming agent and a polymeric substance which impart compressability to the coating.
- EP 361 874 describes a process for the preparation of a core by spraying core granules with a dispersion of a low substituted hydroxypropylcellulose, and if necessary simultaneously applying a dusting powder.
- the dispersion or the dusting powder can be incorporated with an active ingredient.
- the granules obtained exhibit increased granule strength and improved disintegration properties.
- EP 277 874 and EP 475 536 describe a technique for coating of cores with a spraying powder containing an active drug and low substituted hydroxypropyl cellulose. As described in EP 361 874 the cores have increased hardness and favourable disintegration properties.
- EP 277 127 describes controlled release beads coated with a membrane controlling drug release.
- the pharmaceutical active compound is dissolved in a solvent and applied onto an insoluble core material with a porosity of less than 15%.
- the invention provides a novel, controlled release multiple unit dose formulation having clinical and pharmaceutical advantages and with excellent compaction characteristics withstanding alteration of the dissolution profiles, and hence no altering of the bioavailability and clinical effect, during the compaction.
- the active substance is, according to the invention, dispersed in a solution of the hydrophilic polymer and applied to the core.
- powder layering i.e. simultaneously spraying an aqeous solution of the hydrophilic polymer and the active substance as a drug powder onto the core
- a solution of the active substance dissolved in a solvent may also be used, whereby the solution of active substance is applied onto the core.
- a release controlling membrane is further applied to obtain controlled release properties.
- This membrane may also contain additional polymers i.e. usable as coating materials for pharmaceutical purposes.
- the layering technique according to the invention gives multiple unit systems which exhibit sufficient plasticity and flexibility to withstand cracking or rupturing of the release controlling membrane during compaction, i.e. no significant changes in the release profile characteristics of compressed coated pellets relative to uncompressed coated pellets are seen.
- a combination of the polymer layering of the core and a controlled release membrane containing polymeric substances as described above is also favourable to improve the compaction properties of the multiple units.
- the preparation consists of a large number of small inert and insoluble particles, cores, which are layered with an active compound e.g., furosemid, dispersed in a hydrophilic polymer.
- an active compound e.g., furosemid
- the cores have a size of 0.1-2 mm, preferably 0.1-0.5 mm, and most preferably 0.1-0.3 mm, and consists of insoluble inert material, i.e. not soluble in water or physiological fluids, such as glass particles or sand (silicon dioxide) or a soluable core such as sugar spheres.
- the core material used according to the invention may also consist of insoluble inert plastic materials, i.e. spherical or nearly spherical core beads made out of polyvinylchloride, polystyrene or any other pharmaceutical acceptable insoluble synthetical polymeric material made into beads or pellets.
- the core material should have a standardized size and shape, preferably spherical, it should have a high enough density to make possible fluidizing processes.
- the pharmaceutically active compound is applied onto the core material preferably by spraying in a fluidized bed with wurster or top spray technique from a dispersion of the compound in a polymeric solution.
- the particle size of the active compound have to be small, normally less than 100 mm, more preferably less than 30 mm.
- the active compound thereby forms a compact layer together with the polymer on the insoluble core.
- Resulting particles i.e. the controlled release beads have a size of 0.2-3.0 mm, more preferably 0.2-1.5 mm, most preferably 0.2-0.9 mm when filled into capsules and 0.3-1.5 mm for tableting.
- hydrophilic polymer gives the beads plastic properties and even act as a binder.
- Hydrophilic polymers such as polyvinylpyrrolidone, polyalkylene glycol such as polyethylene glycol, gelatine, polyvinyl alcohol, starch and derivatives thereof, cellulose derivatives such as hydroxymethylpropyl- cellulose, hydroxypropylcellulose, carboxymethyl cellulose, methyl cellulose, propyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose or any other pharmaceutically acceptable hydrophilic polymer.
- the core particles may be coated with the active substance dispersed in the hydrophilic polymers by powder layering technique, i.e. the active substances is applied to the core in dry form as powder.
- the polymer is sprayed onto the cores as a solution in such a way that solvent, preferably water, is evaporated, and the polymer is applied to the cores together with the active substance, i.e. forming a homogenous dispersion.
- the ratio of active substance to hydrophilic polymer may be from about 10:1 to about 1:2 for tableting, preferably from about 5:1 to about 1:1, most preferably from about 2:1 to about 1:1, and for filling into capsules preferably from about 10:1 to about 5:1.
- the ratio of active substance to inert non-soluble core particles may be from about 5:1 to about 1:2, preferably from about 2:1 to about 1:2.
- Preferred active substances are furosemid, carbamazepin, ibuprofen, naproxen, probenecid, indometacin, ketoprofen, spironolactone, felodipin, nifedipin, dipyridamole, pindolol, nitrazepam or dextromethorphan, particularly preferred is furosemid.
- the method described above can be used for other pharmaceutical substances as well, provided that they can be dispersed in liquid containing a dissolved hydrophilic polymer, water-based solutions of a hydrophilic polymer is especially preferable. It may even be possible to dissolve the active substance in liquid containing the dissolved polymer prior to spraying onto the cores.
- the beads are coated with a polymeric membrane modifying and controlling the drug release.
- the polymeric membrane can release the drug according to various release profiles, e.g. pH dependent, enteric coating, pH independent, with or without lag time. The most important use is pH independent controlled release in the range of pH 1-8.
- suitable polymeric materials are ethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl phtalate (e.g. HP 55), cellulose acetate phtalate, cellulose acetate trimellitate, Eudragit®RL, Eudragit®RS.
- Ethyl cellulose can be used alone or in a combination with e.g.
- a water soluble polymer such as hydroxypropylmethyl cellulose to adjust the permeability of the coating layer.
- a water soluble polymer such as hydroxypropylmethyl cellulose to adjust the permeability of the coating layer.
- the copolymerisate of acrylic and methacrylic acid esters or other film-formers mentioned herein may be used in combination with a water-soluble polymer.
- polyvinylpyrrolidone polyalkylene glycols such as polyethylene glycol
- cellulose derivatives such as hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, propyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, hydroxymethylcellulose, carboxymethylethylcellulose, methyl-hydroxypropylcellulose.
- Ethyl cellulose is available in grades having different viscosities. Different kinds of viscosity grades are suitable. Even water-based dispersions of ethylcellulose is suitable.
- Eudragit® is the trade name for a number of film coating substances on an acrylic resin basis produced by Rohm Pharma.
- E.g. Eudragit®RL and RS are copolymers synthetized from acrylic and methacrylic acid esters with a low content of quaternary ammonium groups. The molar ratio of these ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:20 for Eudragit®RL and 1:40 for Eudragit®RS resulting in different permeability characteristics.
- Other variants of Eudragit® that can be used are Eudragit®L, Eudragit®S and Eudragit®E.
- Pigments and/or plasticizers may be added to the polymeric solution in order to improve the technical properties of the membrane or modify the release characteristics.
- plasticizers that may be used are citrate esters, acetylated monoglycerides, and glycerinetriacetate.
- coated beads or multiple units described above are favourable in obtaining coated beads filled into capsules or sachets.
- Especially advantageous according to the invention is when the beads are compressed into tablets.
- the pharmaceutical preparation according to the invention it is possible to compress coated beads into tablets without altering the dissolution profile as a consequence of the mechanical stress during the compaction process.
- a combination of the layering method described herein and the controlled release film formulation described herein, comprising the film former and a polymeric substance is especially favourable to obtain the excellent compaction characteristics without altering the dissolution profiles, and hence the bioavailability and clinical effect, during compaction.
- the invention is especially favourable as it is possible to layer core material with active substances such as furosemid etc., or other water insoluble substances, by using a dispersion of the active compound in an aqeous solution of hydrophilic polymer, thus without using a solution in organic liquids.
- a further advantage with the formulation according to the invention is the incorporation of a hydrophilic polymer together with the active pharmaceutical agent. This may give more favourable possibilities to control the dissolution profile of the uncoated and coated beads, for furosemid at pH values lower than about 4.
- the preparation according to the invention is particularly advantageous when controlled and constant release of the therapeutical agent is wanted.
- a method for the controlled release of the therapeutically active substance e.g., furosemid is a further aspect of the invention.
- the formulation above comprising multiple unit dose systems with a release controlling membrane may be prepared by conventional methods such as fluidized beds with top-spray or wurster techniques or powder layering techniques, or any technique well known to one skilled in the art.
- excipients are microcrystalline cellulose, lactose, spray dried lactose, dicalcium phosphate, pregelatinized starch, starches and derivatives thereof such as sodium starch glycolate, maltodextrine, sorbitol, maltitol, cellulose and derivatives thereof, polyethylene glycol, polyvinyl pyrrolidone, compressable sugar, stearic acid, magnesiumstearat, sodium stearylfumarate, talc, colloidal silicone dioxide or any other conventional excipient usable for tablet preparation as will be clear to anyone skilled in the art.
- the excipients i.e. the fillers and binders, comprising the tablet may be used as direct compression excipients or they may be granulated into granules with favourable compression characteristics. Disintegrats may or may not be added. Lubricants will normally be added.
- the amount of fillers and binders, eventually granulated into granules, may be in the range from 25 to 75% of the total tablet weight. To obtain even more favourable compression characteristics it should be between 40 and 75% of the total tablet weight.
- the pharmaceutical preparations according to the present invention may be administered orally.
- Substances such as furosemid, which are excellent as a medicament against cardiovascular diseases such as hypertension, congestive heart failure and oedema, especially for the treatment of hypertension are of special interest.
- Other active substances could be used, e.g. substances for the treatment of diuretic, antiepileptic, antiinflammatoric, analgetic conditions.
- the pellets formed according to Example 1 were compressed into tablets containing furosemid in an amount of 30-60 mg.
- the small beads were thus tabletted by mixing with additives containing e.g. microcrystalline cellulose such as Avicel®, which improves the tableting properites and facilitates the disintegration of the tablet to liberate the individual beads.
- composition for one tablet (mg)
- Example 1 The multiple unit pellets described in Example 1 were mixed with equal amounts of microcrystalline cellulose, and further mixed with 4% sodium starch glycolate (example 5 and example 7).
- Flat faced punch with a diameter of 1.13 cm was used.
- the tablets disintegrated into multiple unit pellets within 30 seconds in 1000 ml purified water at 37° C.
- the beads described were further, as described in example 5, mixed with equal amounts of microcrystalline cellulose, and further mixed with 4% sodium starch glycolate and 0.1% magnesium stearate and compressed into tablets in a singel punch tablet press at a compression pressure of 8 kN ( ⁇ 1 kN) at a compression speed of 35 rpm.
- Flat faced punch with a diameter of 1.13 cm was used.
- the tablets contained 60 mg furosemid.
- Table 1 illustrates the release pattern in vitro for ethylcellulose coated beads.
- pellets when compressed into tablets according to example 5 showed sustained or extended release, properties even when compressed into tablets, whereas pellets prepared according to reference 1 released furosemid relatively fast.
- the amount of ethylcellulose and plasticizer in relation to pellets was 8% by weight in example 5 and reference 1.
- the pellets formed according to Example 1 were filled into hard gelatine capsules.
- the pellets were finally filled into hard gelatine capsules.
- Each capsule contained 60 mg furosemid.
- pellets formed according to the above given examples 2-4 were compressed into tablets containing furosemid in an amount of 60 mg.
- compositions for one tablet (mg)
- the multiple unit pellets described in example 2 were mixed with 60% microcrystalline cellulose, and further mixed with 4% sodium starch glycolate (example 11 and 12) or Crospovidone (example 14).
- Magnesium stearate (example 11 and 12) or sodium stearylfumarate (examples 13 and 14) was admixed and, the mixtures were compressed into tablets in a single punch tablet press at a compression pressure of 8 kN (+/-0.4 kN) at a compression speed of 30 rpm.
- Flat faced punches with a diameter of 1.13 cm were used.
- the multiple unit pellets described in example 3 were mixed with 50 or 60% microcrystalline cellulose, and further mixed with 4% sodium starch glycolate (example 15-17) or Crospovidone (example 19).
- Magnesium stearate (example 15-17) or sodium stearylfumarate (example 18 and 19) was admixed and, the mixtures were compressed into tablets in a single punch tablet press at a compression pressure of 12 kN (+/-0.6 kN) and 16 kN (+/-0.8 kN) at a compression speed of 30 rpm.
- Flat faced punches with a diameter of 1.13 cm were used.
- the multiple unit pellets described in example 4 were mixed with 60% microcrystalline cellulose, and further mixed with 4% sodium starch glycolate (example 20 and 21) or Crospovidone (example 23).
- Magnesium stearate (example 20 and 21) or sodium stearylfumarate (example 22 and 23) was admixed, and the mixtures were compressed into tablets in a single punch tablet press at a compression pressure of 8 kN (+/-0.4 kN) and 16 kN (+/-0.8 kN) at a compression speed of 30 rpm.
- Flat faced punches with a diameter of 1.13 cm were used.
- the tablets disintergrated into multiple unit pellets within 3 minutes in 1000 ml purified water at 37° C.
- composition of one tablet (mg)
- the multiple unit pellets described in example 24 were mixed with 60% microscrystalline cellulose, and further mixed with 4% sodium starch glycolate. Magnesium stearate was admixed and, the mixture was compressed into tablets in a single punch tablet press at a compression pressure of 8 kN (+/-0.4 kN) at a compression speed of 30 rpm. Flat faced punches with a diameter of 1.13 cm were used.
Abstract
Controlled release beads containing a core around which is a drug-containing layer e.g. a layer containing furosemid and a process for their preparation and their use in a pharmaceutical preparation. The controlled release beads have excellent mechanical and release characteristics.
Description
The present invention relates to controlled release beads and a novel pharmaceutical preparation containing a core around which is a drug-containing layer e.g. a layer containing an active substance, i.e. a practically insoluable active substance, preferably furosemid to the use of said preparation and to a process for preparing the same.
The present invention provides a novel a pharmaceutical multiple unit dose preparation with very favourable characteristics which may withstand mechanical stress, i.e. during compaction. These favourable mechanical characteristics are advantageous when dealing with multiple unit dose systems comprising modified or controlled release properties.
A common problem with multiple unit dose systems designated to have modified or controlled release properties is their sensitivity to mechanical stress, e.g. compaction stress, giving rise to rupturing and cracking of the release controlling membrane (Bechard and Leroux 1992) or fragmentation of the core (Magnatiand Celik 1994).
Multiple unit dosage systems may be filled into capsules or sachets, thus requiring sufficient mechanical properties to withstand processing. It may even be advantageous to compact multiple units into tablets, subjecting the systems to significant mechanical stress.
According to the present invention the problem of mechanical suitability mentioned above has been overcome by using inert and non-soluble cores of glass or sand particles or soluble cores such as sugar spheres capable of withstanding mechanical stress, in combination with a plasticizing layer of a hydrophilic polymer containing the active substance, optionally with additional layers of the polymer not containing the active substance, layered between the core and the release controlling membrane.
In abstract PDD 7397 from AAPs congress, USA, Pharmaceutical Research (supplement), 1993, it is described that the coating of pellets provides a physical protection of the pellet core which must remain intact and have suitable mechanical properties in order to be resistant to fragmentation during compaction of the tablet. Fragmentation was, however, found to be between 18 and 42% for ethylcellulose pellets.
In Drug Development and Industrial Pharmacy, 18(8), 1927-1944 (1992), films manufactured from an ethyl cellulose pseudolatex dispersion plasticized with 24% DBS, suitable for the controlled release of chlorpheniramine maleate from small pellets with a size of 250-840 mm, are described. These films do not, however, have the appropriate mechanical properties to withstand compaction forces without rupturing, and the controlled release properties of the compacted pellets are thus lost during the process.
In "Compaction studies on pellets", L. Maganti and M. Celik, International Journal of Pharmaceutics, 95 (1993) 29-42, compaction characteristics of pellets, i.e. cores made from microcrystalline cellulose, dicalciumphosphate, lactose and propranolol HCl, are described, and it is concluded that the pellets exhibit elastic deformation and brittle fragmentation, resulting in compacts of lower tensile strength.
In "Compaction studies on pellets", L. Maganti and M. Celik, International Journal of Pharmaceutics, 103 (1994) 55-67, it is described that the addition of a coating material alters the deformation characteristics of uncoated pellets. Further, it is shown that coated pellets lost their sustained release characteristics after compaction.
U.S. Pat. No. 4,713,248 describes a controlled release multiple unit formulation containing an active substance coated with a water based film comprising a homogeneous combination of water-dispersable film forming agent and a polymeric substance which impart compressability to the coating.
EP 361 874 describes a process for the preparation of a core by spraying core granules with a dispersion of a low substituted hydroxypropylcellulose, and if necessary simultaneously applying a dusting powder. The dispersion or the dusting powder can be incorporated with an active ingredient. The granules obtained exhibit increased granule strength and improved disintegration properties.
EP 277 874 and EP 475 536 describe a technique for coating of cores with a spraying powder containing an active drug and low substituted hydroxypropyl cellulose. As described in EP 361 874 the cores have increased hardness and favourable disintegration properties.
EP 277 127 describes controlled release beads coated with a membrane controlling drug release. The pharmaceutical active compound is dissolved in a solvent and applied onto an insoluble core material with a porosity of less than 15%.
There is not described anywhere in the prior art a controlled release multiple unit system or beads comprising a soluble core, alternatively an insoluble core with a porosity of less than 15% layered with a pharmaceutical practically insoluable (USP XXIII) active substance dispersed in or homogeneously mixed with a hydrophilic polymer, thereby exhibiting excellent mechanical properties.
Outline of the invention
We have now surprisingly found that the problem mentioned above can be solved by the new pharmaceutical preparation according to the present invention. The invention provides a novel, controlled release multiple unit dose formulation having clinical and pharmaceutical advantages and with excellent compaction characteristics withstanding alteration of the dissolution profiles, and hence no altering of the bioavailability and clinical effect, during the compaction.
When forming the pharmaceutical preparation according to the invention it has surprisingly been found that the addition of a hydrophilic polymer in a layer together with the active substance in specified ratios and the ratio of active substance to the core being within specified ratios in the beads, gives favourable mechanical properties withstanding cracking, especially of the release controlling membrane, when exposed to mechanical stresses, e.g. during filling in capsules or sachets or during compaction.
The active substance is, according to the invention, dispersed in a solution of the hydrophilic polymer and applied to the core. By using powder layering, i.e. simultaneously spraying an aqeous solution of the hydrophilic polymer and the active substance as a drug powder onto the core, the principle according to the invention may be obtained. A solution of the active substance dissolved in a solvent may also be used, whereby the solution of active substance is applied onto the core. A release controlling membrane is further applied to obtain controlled release properties. This membrane may also contain additional polymers i.e. usable as coating materials for pharmaceutical purposes.
The layering technique according to the invention, gives multiple unit systems which exhibit sufficient plasticity and flexibility to withstand cracking or rupturing of the release controlling membrane during compaction, i.e. no significant changes in the release profile characteristics of compressed coated pellets relative to uncompressed coated pellets are seen. A combination of the polymer layering of the core and a controlled release membrane containing polymeric substances as described above is also favourable to improve the compaction properties of the multiple units.
The preparation consists of a large number of small inert and insoluble particles, cores, which are layered with an active compound e.g., furosemid, dispersed in a hydrophilic polymer.
The cores have a size of 0.1-2 mm, preferably 0.1-0.5 mm, and most preferably 0.1-0.3 mm, and consists of insoluble inert material, i.e. not soluble in water or physiological fluids, such as glass particles or sand (silicon dioxide) or a soluable core such as sugar spheres. The core material used according to the invention may also consist of insoluble inert plastic materials, i.e. spherical or nearly spherical core beads made out of polyvinylchloride, polystyrene or any other pharmaceutical acceptable insoluble synthetical polymeric material made into beads or pellets.
The core material should have a standardized size and shape, preferably spherical, it should have a high enough density to make possible fluidizing processes.
The pharmaceutically active compound is applied onto the core material preferably by spraying in a fluidized bed with wurster or top spray technique from a dispersion of the compound in a polymeric solution. To allow the spraying process from a dispersion of the particles the particle size of the active compound have to be small, normally less than 100 mm, more preferably less than 30 mm.
The active compound thereby forms a compact layer together with the polymer on the insoluble core. Resulting particles i.e. the controlled release beads have a size of 0.2-3.0 mm, more preferably 0.2-1.5 mm, most preferably 0.2-0.9 mm when filled into capsules and 0.3-1.5 mm for tableting.
The hydrophilic polymer gives the beads plastic properties and even act as a binder. Hydrophilic polymers such as polyvinylpyrrolidone, polyalkylene glycol such as polyethylene glycol, gelatine, polyvinyl alcohol, starch and derivatives thereof, cellulose derivatives such as hydroxymethylpropyl- cellulose, hydroxypropylcellulose, carboxymethyl cellulose, methyl cellulose, propyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose or any other pharmaceutically acceptable hydrophilic polymer.
The core particles may be coated with the active substance dispersed in the hydrophilic polymers by powder layering technique, i.e. the active substances is applied to the core in dry form as powder. At the same time the polymer is sprayed onto the cores as a solution in such a way that solvent, preferably water, is evaporated, and the polymer is applied to the cores together with the active substance, i.e. forming a homogenous dispersion.
The ratio of active substance to hydrophilic polymer may be from about 10:1 to about 1:2 for tableting, preferably from about 5:1 to about 1:1, most preferably from about 2:1 to about 1:1, and for filling into capsules preferably from about 10:1 to about 5:1.
The ratio of active substance to inert non-soluble core particles may be from about 5:1 to about 1:2, preferably from about 2:1 to about 1:2.
Preferred active substances are furosemid, carbamazepin, ibuprofen, naproxen, probenecid, indometacin, ketoprofen, spironolactone, felodipin, nifedipin, dipyridamole, pindolol, nitrazepam or dextromethorphan, particularly preferred is furosemid.
The method described above can be used for other pharmaceutical substances as well, provided that they can be dispersed in liquid containing a dissolved hydrophilic polymer, water-based solutions of a hydrophilic polymer is especially preferable. It may even be possible to dissolve the active substance in liquid containing the dissolved polymer prior to spraying onto the cores.
The beads are coated with a polymeric membrane modifying and controlling the drug release. The polymeric membrane can release the drug according to various release profiles, e.g. pH dependent, enteric coating, pH independent, with or without lag time. The most important use is pH independent controlled release in the range of pH 1-8. Examples of suitable polymeric materials are ethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl phtalate (e.g. HP 55), cellulose acetate phtalate, cellulose acetate trimellitate, Eudragit®RL, Eudragit®RS. Ethyl cellulose can be used alone or in a combination with e.g. a water soluble polymer such as hydroxypropylmethyl cellulose to adjust the permeability of the coating layer. Even the copolymerisate of acrylic and methacrylic acid esters or other film-formers mentioned herein may be used in combination with a water-soluble polymer. Other pharmaceutically acceptable polymers which could be incorporated in the film layer are polyvinylpyrrolidone, polyalkylene glycols such as polyethylene glycol, and cellulose derivatives such as hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, propyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethylhydroxyethyl cellulose, hydroxymethylcellulose, carboxymethylethylcellulose, methyl-hydroxypropylcellulose.
Ethyl cellulose is available in grades having different viscosities. Different kinds of viscosity grades are suitable. Even water-based dispersions of ethylcellulose is suitable.
Eudragit® is the trade name for a number of film coating substances on an acrylic resin basis produced by Rohm Pharma. E.g. Eudragit®RL and RS are copolymers synthetized from acrylic and methacrylic acid esters with a low content of quaternary ammonium groups. The molar ratio of these ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:20 for Eudragit®RL and 1:40 for Eudragit®RS resulting in different permeability characteristics. Other variants of Eudragit® that can be used are Eudragit®L, Eudragit®S and Eudragit®E.
Pigments and/or plasticizers may be added to the polymeric solution in order to improve the technical properties of the membrane or modify the release characteristics. Examples of plasticizers that may be used are citrate esters, acetylated monoglycerides, and glycerinetriacetate.
Organic solutions or water-based dispersions of the polymers, as will be appreciated by the man skilled in the art (e.g. Aquacoat®, Surelease®, Eudragit®E 30 D, Eudragit®L 30 D) could be used for obtaining the membrane modifying and controlling the release of the active substance.
By using the pharmaceutical preparation according to the invention several advantages are obtained.
The coated beads or multiple units described above are favourable in obtaining coated beads filled into capsules or sachets. Especially advantageous according to the invention is when the beads are compressed into tablets. By using the pharmaceutical preparation according to the invention it is possible to compress coated beads into tablets without altering the dissolution profile as a consequence of the mechanical stress during the compaction process. A combination of the layering method described herein and the controlled release film formulation described herein, comprising the film former and a polymeric substance is especially favourable to obtain the excellent compaction characteristics without altering the dissolution profiles, and hence the bioavailability and clinical effect, during compaction.
Use of organic solvents give rise to enviromental pollution, danger of explosions and hazard unless costly recycling procedures are used. From an enviromental point of view the invention is especially favourable as it is possible to layer core material with active substances such as furosemid etc., or other water insoluble substances, by using a dispersion of the active compound in an aqeous solution of hydrophilic polymer, thus without using a solution in organic liquids.
By using powder layering, i.e. simultaneously spraying of an aqueous solution of the hydrophilic polymer and the active substance as dry powder onto the core material, similar enviromental advantages are obtained.
A further advantage with the formulation according to the invention is the incorporation of a hydrophilic polymer together with the active pharmaceutical agent. This may give more favourable possibilities to control the dissolution profile of the uncoated and coated beads, for furosemid at pH values lower than about 4.
The preparation according to the invention is particularly advantageous when controlled and constant release of the therapeutical agent is wanted. A method for the controlled release of the therapeutically active substance e.g., furosemid is a further aspect of the invention. Thus giving flexibility and favourable mechanical properties in such a way that cracking or rupturing of the release controlling membrane is avoided.
Pharmaceutical preparations
The formulation above comprising multiple unit dose systems with a release controlling membrane may be prepared by conventional methods such as fluidized beds with top-spray or wurster techniques or powder layering techniques, or any technique well known to one skilled in the art.
When the pellets are compressed into tablets they are blended with conventional excipents to obtain favourable filling, binding, lubrication and disintegration properties. Examples of excipients are microcrystalline cellulose, lactose, spray dried lactose, dicalcium phosphate, pregelatinized starch, starches and derivatives thereof such as sodium starch glycolate, maltodextrine, sorbitol, maltitol, cellulose and derivatives thereof, polyethylene glycol, polyvinyl pyrrolidone, compressable sugar, stearic acid, magnesiumstearat, sodium stearylfumarate, talc, colloidal silicone dioxide or any other conventional excipient usable for tablet preparation as will be clear to anyone skilled in the art.
The excipients, i.e. the fillers and binders, comprising the tablet may be used as direct compression excipients or they may be granulated into granules with favourable compression characteristics. Disintegrats may or may not be added. Lubricants will normally be added. The amount of fillers and binders, eventually granulated into granules, may be in the range from 25 to 75% of the total tablet weight. To obtain even more favourable compression characteristics it should be between 40 and 75% of the total tablet weight.
The pharmaceutical preparations according to the present invention may be administered orally. Substances, such as furosemid, which are excellent as a medicament against cardiovascular diseases such as hypertension, congestive heart failure and oedema, especially for the treatment of hypertension are of special interest. Other active substances could be used, e.g. substances for the treatment of diuretic, antiepileptic, antiinflammatoric, analgetic conditions.
The following examples will describe the invention in more detail.
Cores:
______________________________________ Silicone dioxide (0.1-0.3 mm) 1000 g Water, purified 2000 g Furosemid (90% <25 μm) 1000 g Polyvinyl pyrrolidone, K-30 500 g ______________________________________
Polymeric Layer:
______________________________________ Ethylcellulose 60.3 g Hydroxypropylmethylcellulose 13.3 g Triethylcitrate 6.0 g Ethanol 1446.5 g ______________________________________
______________________________________ Silicone dioxide (0.1-0.3 mm) 800 g Water, purified 1480 g Furosemid (90% <10 μm) 800 g Polyvinyl pyrrolidone, K-30 400 g ______________________________________
Polymeric Layers:
______________________________________ Ethylcellulose 292 g Hydroxypropylcellulose 108 g Ethanol 3500 g ______________________________________
______________________________________ Ethylcellulose 266 g Hydroxypropylcellulose 134 g Ethanol 3500 g ______________________________________
______________________________________ Etylcellulose 240 g Hydroxypropylcellulose 160 g Ethanol 3500 g ______________________________________
In a fluidized bed granulator furosemid dispersed in a solution of polyvinyl pyrrolidone (K-30) in water was sprayed onto the cores of silicone dioxide. 800 g of the beads so formed were covered with the polymeric solution containing ethyl cellulose and hydroxypropylmethylcellulose, and triethylcitrate in Example 1, ethyl cellulose and hydroxypropylcellulose in Example 24, by spraying a solution of the mentioned substances in ethanol.
The pellets formed according to Example 1 were compressed into tablets containing furosemid in an amount of 30-60 mg. The small beads were thus tabletted by mixing with additives containing e.g. microcrystalline cellulose such as Avicel®, which improves the tableting properites and facilitates the disintegration of the tablet to liberate the individual beads.
Composition for one tablet (mg)
______________________________________ Coated pellets (Example 1) 171.8 Microcrystalline cellulose (Avicel ® PH 200) 171.8 Sodium starch glycolate 13.7 Magnesium stearate 0.4 ______________________________________
______________________________________ Coated pellets (Example 1) 171.8 Microcrystalline cellulose (Avicel ® PH 102) 171.8 Sodium stearylfumarate 0.3 ______________________________________
______________________________________ Coated pellets (Example 1) 171.8 Microcrystalline cellulose (Avicel ® PH 102) 171.8 Sodium starch glycolate 13.7 Sodium stearylfumarate 0.3 ______________________________________
The multiple unit pellets described in Example 1 were mixed with equal amounts of microcrystalline cellulose, and further mixed with 4% sodium starch glycolate (example 5 and example 7). Magnesium stearate (example 5) or sodium stearylfumarate (example 6 and example 7) was admixed, and the mixtures were compressed into tablets in a singel punch tablet press at a compression pressure of 8 kN(±1 kN) and 4 kN(±1 kN) at a compression speed of 35 rpm. Flat faced punch with a diameter of 1.13 cm was used.
Characterization of the tablets according to example 5
The tablets disintegrated into multiple unit pellets within 30 seconds in 1000 ml purified water at 37° C.
The in vitro dissolution, in accordance with USP Paddle method, 1000 ml buffer pH 6.8, of the tablets compressed at 8 kN, containing 60 mg furosemid, is shown in Table 1.
Reference 1
Cores:
______________________________________ Silicone dioxide (0.15-0.25 mm) 1000 g Water, purified 1950 g Furosemid (90% <25 μm) 1000 g Polyvinyl pyrrolidone, K-90 50 g ______________________________________
Polymeric Layer:
______________________________________ Ethylcellulose dispersion, 30% (Aquacoat ®) 170 g Acetyltributyl citrate 13 g ______________________________________
In a fluidized bed granulator furosemid dispersed in a solution of polyvinyl pyrrolidone (K-90) in water was sprayed onto the cores of silicone dioxide. 800 g of the beads so formed were coated with the aqueous polymeric ethylcellulose dispersion, (Aquacoat®) containing additional plasticizer acetyltributyl citrate. After the coating procedure the coated pellets were heated for 17 hours at 70° C.
The beads described were further, as described in example 5, mixed with equal amounts of microcrystalline cellulose, and further mixed with 4% sodium starch glycolate and 0.1% magnesium stearate and compressed into tablets in a singel punch tablet press at a compression pressure of 8 kN (±1 kN) at a compression speed of 35 rpm. Flat faced punch with a diameter of 1.13 cm was used. The tablets contained 60 mg furosemid.
Table 1 illustrates the release pattern in vitro for ethylcellulose coated beads.
TABLE 1 ______________________________________ Dissolution of furosemid from furosemid tablets, 60 mg, prepared according to example 5 and reference 1. Percentage furosemid released at pH 6.8 (n = 3) after: 0.5h 1h 2h 3h 5h 10h ______________________________________ Example 5 18% 33% 52% 65% 79% >90% Reference 1 41% 60% >80% ______________________________________ (n = 2)
As is shown in table 1 the pellets when compressed into tablets according to example 5, showed sustained or extended release, properties even when compressed into tablets, whereas pellets prepared according to reference 1 released furosemid relatively fast. The amount of ethylcellulose and plasticizer in relation to pellets was 8% by weight in example 5 and reference 1.
The pellets formed according to Example 1 were filled into hard gelatine capsules.
Cores:
______________________________________ Silicone dioxide (0.1-0.3 mm) 1000 g Water, purified 1900 g Furosemid (90% <25 μm) 1000 g Polyvinyl pyrrolidone, K-90 100 g ______________________________________
Polymeric Layer:
______________________________________ Ethylcellulose dispersion, 30% (Aquacoat) 128 g Acetyltributyl citrate 10 g ______________________________________
______________________________________ Ethylcellulose dispersion, 30% (Aquacoat) 170 g Acetyltributyl citrate 13 g ______________________________________
In a fluidized bed granulator furosemid dispersed in a solution of polyvinyl pyrrolidone (K-90) in water was sprayed onto the cores of silicone dioxide. 800 g of the beads so formed were coated with the aqueous polymeric ethylcellulose dispersion, (Aquacoat) containing additional plastizer acetyltributyl citrate. After the coating procedure the coated pellets were heated for 17 hours at 70° C.
The pellets were finally filled into hard gelatine capsules. Each capsule contained 60 mg furosemid.
The in vitro dissolution of the capsules in accordance with USP Paddle method, 1000 ml buffer pH 6.8, is shown in Table 2.
TABLE 2 ______________________________________ Dissolution of furosemid from furosemid capsules, 60 mg, prepared according to examples 9 and 10. Percentage furosemid released at pH 6.8 (n = 6) after: 0.5h 1h 2h 3h 5h 10h 13.3h ______________________________________ Example 9 31% 48% 67% 75% >90% -- -- Example 10 10% 19% 33% 44% 60% 70% >80% ______________________________________
The pellets formed according to the above given examples 2-4 were compressed into tablets containing furosemid in an amount of 60 mg.
Compositions for one tablet (mg)
______________________________________ Coated pellets (example 2) 221 Microcrystalline cellulose (Avicel sp. coarse grade) 331 Sodium starch glycolate 22 Magnesium stearate 0.28 ______________________________________
______________________________________ Coated pellets (example 2) 221 Microcrystalline cellulose (Avicel PH 302) 331 Sodium starch glycolute 22 Magnesium stearate 0.28 ______________________________________
______________________________________ Coated pellets (example 2) 221 Microcrystalline cellulose (Avicel sp. coarse grade) 331 Sodium stearylfumarate 0.20 ______________________________________
______________________________________ Coated pellets (example 2) 221 Microcrystalline cellulose (Avicel sp. coarse grade) 331 Crospovidone 22 Sodium stearylfumarate 0.20 ______________________________________
The multiple unit pellets described in example 2 were mixed with 60% microcrystalline cellulose, and further mixed with 4% sodium starch glycolate (example 11 and 12) or Crospovidone (example 14). Magnesium stearate (example 11 and 12) or sodium stearylfumarate (examples 13 and 14) was admixed and, the mixtures were compressed into tablets in a single punch tablet press at a compression pressure of 8 kN (+/-0.4 kN) at a compression speed of 30 rpm. Flat faced punches with a diameter of 1.13 cm were used.
______________________________________ Coated pellets (example 3) 221 mg Microcrystalline cellulose (Avicel sp. coarse grade) 221 mg Sodium starch glycolate 18 mg Magnesium stearate 0.22 mg ______________________________________
______________________________________ Coated pellets (example 3) 221 mg Microcrystalline cellulose (Avicel PH 302) 221 mg Sodium starch glycolate 18 mg Magnesium stearate 0.22 mg ______________________________________
______________________________________ Coated pellets (example 3) 221 mg Microcrystalline cellulose (Avicel sp. coarse grade) 331 mg Magnesium stearate 0.28 mg Sodium starch glycolate 22 mg ______________________________________
______________________________________ Coated pellets (example 3) 221 mg Microcrystalline cellulose (Avicel sp. coarse grade) 221 mg Sodium stearylfumarate 0.18 mg ______________________________________
______________________________________ Coated pellets (example 3) 221 mg Microcrystalline cellulose (Avicel sp. coarse grade) 221 mg Crospovidone 18 mg Sodium stearylfumarate 0.18 mg ______________________________________
The multiple unit pellets described in example 3 were mixed with 50 or 60% microcrystalline cellulose, and further mixed with 4% sodium starch glycolate (example 15-17) or Crospovidone (example 19). Magnesium stearate (example 15-17) or sodium stearylfumarate (example 18 and 19) was admixed and, the mixtures were compressed into tablets in a single punch tablet press at a compression pressure of 12 kN (+/-0.6 kN) and 16 kN (+/-0.8 kN) at a compression speed of 30 rpm. Flat faced punches with a diameter of 1.13 cm were used.
______________________________________ Coated pellets (example 4) 223 mg Microcrystalline cellulose (Avicel sp. coarse grade) 334 mg Sodium starch glycolate 22 mg Magnesium stearate 0.28 mg ______________________________________
______________________________________ Coated pellets (example 4) 223 mg Microcrystalline cellulose (Avicel PH 302) 334 mg Sodium starch glycolate 22 mg Magnesium stearate 0.28 mg ______________________________________
______________________________________ Coated pellets (example 4) 223 mg Microcrystalline cellulose (Avicel sp. coarse grade) 334 mg Sodium stearylfumarate 0.20 mg ______________________________________
______________________________________ Coated pellets (example 4) 223 mg Microcrystalline cellulose (Avicel sp. coarse grade) 334 mg Crospovidone 22 mg Sodium stearylfumarate 0.28 mg ______________________________________
The multiple unit pellets described in example 4 were mixed with 60% microcrystalline cellulose, and further mixed with 4% sodium starch glycolate (example 20 and 21) or Crospovidone (example 23). Magnesium stearate (example 20 and 21) or sodium stearylfumarate (example 22 and 23) was admixed, and the mixtures were compressed into tablets in a single punch tablet press at a compression pressure of 8 kN (+/-0.4 kN) and 16 kN (+/-0.8 kN) at a compression speed of 30 rpm. Flat faced punches with a diameter of 1.13 cm were used.
Characterization of the tablets formed according to formulation examples 11 -21
The tablets disintergrated into multiple unit pellets within 3 minutes in 1000 ml purified water at 37° C.
The in vitro dissolution, in accordance with USP Paddle method, 1000 ml buffer pH 6.8, of the tablets compressed at 8, 12 and 16 kN, containing 60 mg furosemid, is shown in Table 3.
TABLE 3 __________________________________________________________________________ Percentage furosemide at pH 6.8 (n = 3) Compaction Percent furosemide dissolved at pH 6.8 Pressure 180 Examples (kN) 30 60 120 (min) 300 600 840 1200 __________________________________________________________________________ 2 -- 1 2 4 8 19 56 80 96 11 8 1 2 5 10 24 69 91 100 12 8 1 2 5 9 23 67 90 98.4 3 -- 13 22 56 88 100 15 12 12 21 50 82 100 16 12 9 18 46 79 100 17 16 8 17 49 84 100 4 -- 14 34 83 100 20 8 11 36 90 100 20 16 12 39 97 100 21 8 11 38 98 100 __________________________________________________________________________
______________________________________ Silicone dioxide (0.1-0.3 mm) 800 g Water, purified 1480 g Naproxen 800 g Polyvinyl pyrrolidone, k-30 400 g ______________________________________
Polymeric layer:
______________________________________ Ethylcellulose 266 g Hydroxypropylcellulose 134 g Ethanol 3500 g ______________________________________
Composition of one tablet (mg)
______________________________________ Coated pellets (example 24) 247 Microcrystalline cellulose (Avicel sp. coarse grade) 370 Sodium starch glycolate 25 Magnesium stearate 0.31 ______________________________________
The multiple unit pellets described in example 24 were mixed with 60% microscrystalline cellulose, and further mixed with 4% sodium starch glycolate. Magnesium stearate was admixed and, the mixture was compressed into tablets in a single punch tablet press at a compression pressure of 8 kN (+/-0.4 kN) at a compression speed of 30 rpm. Flat faced punches with a diameter of 1.13 cm were used.
The in vitro dissolution, in accordance with USP paddle method, 1000 ml buffer pH 7.4, of the tablets compressed at 8 kN, containing 60 mg Naproxen, is shown in Table 4.
TABLE 4 ______________________________________ Percentage naproxen at pH 7.4 (n = 3) Exampel Compaction Percent naproxen dissolved at pH 7.4 24 Pressure 30 60 120 180 300 ______________________________________ Pellets -- 10 30 76 96 99 Tablets 8 9 32 79 98 100 ______________________________________
Conclusion
By using the principles described herein reproducible and controllable production processes for multiple unit systems compressed into tablets or filled into capsules or sachets are obtained. Further this new formulation principle gives excellent multiple unit systems withstanding mechanical stresses and giving enough flexibility and plasticity to avoid cracking or rupturing of release controlling membranes.
Claims (22)
1. A controlled release bead or multiple thereof having a size varying between 0.2-3.0 mm, comprising:
(a) a multiple of a core unit of an insoluble or soluble inert material of a size of 0.1-2 mm;
(b) a first layer on the core unit comprising an active ingredient dispersed in a hydrophilic polymer; wherein the ratio of the active ingredient to the hydrophilic polymer is in the range of from about 10:1 to about 1:1, and the ratio of the active ingredient to the inert insoluble or soluble core is in the range of from about 5:1 to about 1:2;
(c) an optional second layer of hydrophilic polymer covering the first layer; and
(d) an outermost membrane layer effective for controlled release of the active ingredient;
the bead or multiplicity thereof exhibiting improved mechanical and release properties so as to withstand alteration in terms of bioavailability and clinical efficacy due to compaction into a multiple unit tablet.
2. The controlled release bead or multiple thereof according to claim 1 wherein the ratio of the active ingredient to hydrophilic polymer is in the range of from 5:1 to about 1:1.
3. Controlled release beads according to claim 1, wherein the cores have a size of 0.1-0.3 mm.
4. The controlled release bead or multiple thereof according to claim 3, wherein the core unit comprises as a first layer the active ingredient dispersed in a hydrophilic polymer; and an outer membrane for controlled release.
5. The controlled release bead or multiplicity thereof according to claim 4, wherein the hydrophilic polymer is polyvinyl pyrrolidone.
6. The controlled release bead or multiplicity thereof according to claim 1, wherein the beads have a size of 0.2-1.5 mm.
7. The controlled release bead or multiplicity thereof according to claim 4, wherein the active substance is furosemid.
8. A process for preparation of the controlled release bead or multiple thereof according to claim 1, comprising the steps of:
(a) dispersing the active ingredient having a particle size of less than 100 μm in a solution of a hydrophilic polymer
(b) spraying a first layer of the dispersal of active ingredient in hydrophilic polymer onto the insoluble inert core unit or multiple thereof, and
(c) spraying the outer membrane for controlled release onto the first layer.
9. A process according to claim 8, wherein the hydrophilic polymer is polyvinyl pyrrolidone.
10. A pharmaceutical preparation comprising controlled release beads according to claim 1, optionally together with pharmaceutically acceptable excipients.
11. A pharmaceutical preparation according to claim 10, wherein the active substance is furosemid.
12. A pharmaceutical preparation according to any one of claims 10 or 11, wherein the amount of active substance is in the range 20-100 mg.
13. A pharmaceutical preparation according to claim 12, wherein the amount of active substance is in the range 30-60 mg.
14. The pharmaceutical preparation according to claim 10, wherein the beads have improved properties so as to resist alterations in terms of bioavailability and clinical efficacy during compaction into tablets.
15. A pharmaceutical preparation according to claim 14, wherein the ratio of active substances to hydrophilic polymer is of from about 5:1 to about 1:1 and the ratio of active substance to inert non-soluble core particles is of from about 2:1 to about 1:2.
16. A pharmaceutical preparation according to claim 15, wherein the ratio of active substance to hydrophilic polymer is of from about 2:1 to about 1:1 and the ratio of active substance to inert non-soluble core particles is of from about 2:1 to about 1:2.
17. A pharmaceutical preparation according to claim 12, in the form of capsules.
18. A pharmaceutical preparation according to claim 17, wherein the ratio of active substance to hydrophilic polymer is of from about 10:1 to about 5:1 and the ratio of active substance to inert non-soluble core particles is of from about 2:1 to about 1:2.
19. A pharmaceutical preparation according to claims 10-18 which is administered orally.
20. A process for the manufacture of a pharmaceutical preparation according to claim 14, wherein the cores are compressed into tablets by mixing with additives.
21. A method for the treatment of hypertension, oedemas and congestive heart failure wherein a pharmaceutical preparation according to claim 10-19 is administered to a host in the need of such treatment.
22. The process according to claim 8, wherein a second layer of the hydrophilic polymer is sprayed onto the first layer before adding the controlled release membrane onto the bead core unit.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9402422A SE9402422D0 (en) | 1994-07-08 | 1994-07-08 | New beads for controlled release and a pharmaceutical preparation containing the same |
SE9402422 | 1994-07-08 | ||
PCT/SE1995/000676 WO1996001621A1 (en) | 1994-07-08 | 1995-06-07 | New beads for controlled release and a pharmaceutical preparation containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US5783215A true US5783215A (en) | 1998-07-21 |
Family
ID=20394677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/464,773 Expired - Fee Related US5783215A (en) | 1994-07-08 | 1995-06-07 | Pharmaceutical preparation |
Country Status (23)
Country | Link |
---|---|
US (1) | US5783215A (en) |
EP (1) | EP0723434A1 (en) |
JP (1) | JPH09502738A (en) |
CN (1) | CN1134108A (en) |
AU (1) | AU700949B2 (en) |
BR (1) | BR9506026A (en) |
CA (1) | CA2170526A1 (en) |
CZ (1) | CZ73196A3 (en) |
EE (1) | EE03280B1 (en) |
FI (1) | FI961056A (en) |
HU (1) | HUT75772A (en) |
IL (1) | IL114448A (en) |
MX (1) | MX9600858A (en) |
NO (1) | NO960837D0 (en) |
NZ (1) | NZ289947A (en) |
PL (1) | PL313386A1 (en) |
RU (1) | RU2141822C1 (en) |
SE (1) | SE9402422D0 (en) |
SK (1) | SK30396A3 (en) |
TR (1) | TR199500822A2 (en) |
TW (1) | TW460300B (en) |
WO (1) | WO1996001621A1 (en) |
ZA (1) | ZA955545B (en) |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
US20030133982A1 (en) * | 2001-12-20 | 2003-07-17 | Heimlich John M. | Zero-order sustained release dosage forms and method of making same |
WO2003103637A2 (en) * | 2002-01-10 | 2003-12-18 | Ranbaxy Laboratories Limited | Modified release, multiple unit drug delivery systems |
US20040005361A1 (en) * | 2002-07-06 | 2004-01-08 | Sanjeev Khandelwal | Pharmaceutical preparations |
US20040057999A1 (en) * | 1997-01-17 | 2004-03-25 | Andre Stamm | Fenofibrate compositions having enhanced bioavailability |
US20040185111A1 (en) * | 2002-12-10 | 2004-09-23 | Rubino Orapin P. | Method of preparing biologically active formulations |
US6805881B1 (en) * | 1998-09-18 | 2004-10-19 | Bayer Aktiengesellschaft | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same |
WO2004105735A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical compositions of tolterodine and processes for their preparation |
FR2861990A1 (en) * | 2003-11-10 | 2005-05-13 | Nouveaux Produits Pharma | Low-dose tablets for oral administration are produced by direct compression of microgranules comprising an active ingredient layer on a release-modifying polymer layer on an inert support |
US20050175695A1 (en) * | 2003-11-25 | 2005-08-11 | Catherine Castan | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
US7022342B2 (en) * | 2002-03-28 | 2006-04-04 | Andrx Corporation, Inc. | Controlled release oral dosage form of beta-adrenergic blocking agents |
US20060183779A1 (en) * | 2002-03-07 | 2006-08-17 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US20060286163A1 (en) * | 1998-03-04 | 2006-12-21 | Thakur Madhav S | Pharmaceutical composition of topiramate |
BG65149B1 (en) * | 1998-11-11 | 2007-04-30 | Pharmacia Ab | New controlled release bead, a method of producing the same and formulation comprising it |
US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
US20070224269A1 (en) * | 2004-06-10 | 2007-09-27 | Rubino Orapin P | Controlled Release Pharmaceutical Formulation |
US20070248670A1 (en) * | 2006-04-21 | 2007-10-25 | Van Den Heuvel Dennie J M | Tolterodine beads |
US20070259041A1 (en) * | 2006-05-05 | 2007-11-08 | Wyeth | Solid dosage formulations |
US20090017111A1 (en) * | 2007-07-03 | 2009-01-15 | Van Den Heuvel Dennie J M | Tolterodine bead |
US20090068263A1 (en) * | 2006-04-20 | 2009-03-12 | Themis Laboratories Private Limited | Multiple unit compositions |
US20090252787A1 (en) * | 2006-07-28 | 2009-10-08 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
WO2011013082A1 (en) | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
US20110189280A1 (en) * | 2008-08-29 | 2011-08-04 | Allan James Clarke | Dosage form comprising 1-isopropyl-4-hexahydro-1h-1,4-diazepine or a salt thereof |
WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US8603520B2 (en) | 2003-06-26 | 2013-12-10 | Intellipharmaceutics Corp. | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
US20140112995A1 (en) * | 2009-07-31 | 2014-04-24 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
EP2886110A1 (en) | 2013-12-23 | 2015-06-24 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
US9078827B2 (en) | 2006-05-12 | 2015-07-14 | Isa Odidi | Pharmaceutical composition having reduced abuse potential |
US9408858B2 (en) | 2007-04-25 | 2016-08-09 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in CKD |
US9561188B2 (en) | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
WO2017125929A1 (en) | 2016-01-20 | 2017-07-27 | Galmed Research And Development Ltd. | Treatment for modulating gut microbiota |
US9861644B2 (en) | 2013-03-15 | 2018-01-09 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US9943530B2 (en) | 2006-02-03 | 2018-04-17 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
US10302660B2 (en) | 2008-04-02 | 2019-05-28 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US10668089B2 (en) | 2006-06-21 | 2020-06-02 | Opko Ireland Global Holdings, Ltd. | Method of treating and preventing secondary hyperparathyroidism |
US11077055B2 (en) | 2015-04-29 | 2021-08-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
US11801253B2 (en) | 2007-04-25 | 2023-10-31 | Opko Renal, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2758461A1 (en) * | 1997-01-17 | 1998-07-24 | Pharma Pass | PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND PROCESS FOR PREPARING THE SAME |
CA2230748C (en) * | 1997-03-14 | 2010-08-03 | American Home Products Corporation | Rapamycin formulations for oral administration |
SE9702533D0 (en) | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
FR2771291B1 (en) * | 1997-11-21 | 2000-02-25 | Ethypharm Lab Prod Ethiques | SPHEROIDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS |
CO5070568A1 (en) | 1998-05-22 | 2001-08-28 | Eurand Internatrional Spa | LAYER AND APPLIANCE APPLICATION PROCESS FOR EFFECT |
US7863331B2 (en) | 1999-07-09 | 2011-01-04 | Ethypharm | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
FR2795961B1 (en) | 1999-07-09 | 2004-05-28 | Ethypharm Lab Prod Ethiques | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED FENOFIBRATE, A SURFACTANT AND A BINDING CELLULOSIC DERIVATIVE AND PREPARATION METHOD |
PT1227806E (en) | 1999-11-11 | 2005-10-31 | Pfizer Health Ab | PHARMACEUTICAL FORMULA CONTAINING TOLTERODINE AND ITS UTILIZATION |
CA2456034A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
CO5400144A1 (en) | 2002-03-11 | 2004-05-31 | Novartis Ag | ORGANIC COMPOUNDS |
FR2842736B1 (en) * | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF A PLURALITY OF MICROCAPSULES FOR PROLONGED RELEASE OF LOW SOLUBLE ACTIVE (S) PRINCIPLE (S) |
JP2006516574A (en) | 2003-02-05 | 2006-07-06 | テバ ファーマシューティカル インダストリーズ リミティド | Lansoprazole stabilization method |
DK1915137T3 (en) | 2005-08-10 | 2013-11-04 | Add Advanced Drug Delivery Technologies Ltd | Controlled-release oral preparation |
WO2007097770A1 (en) * | 2006-02-24 | 2007-08-30 | Teva Pharmaceutical Industries Ltd. | Metoprolol succinate e.r. tablets and methods for their preparation |
CA2629099A1 (en) * | 2008-04-01 | 2009-10-01 | Pharmascience Inc. | Novel oral controlled release pharmaceutical formulations |
GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
PL3398587T3 (en) * | 2015-12-28 | 2024-01-22 | Ssp Co., Ltd., Japan | Compacted pharmaceutical preparation |
CN108272766B (en) * | 2018-03-21 | 2020-07-07 | 江苏四环生物制药有限公司 | Mecobalamin dispersion delayed-release tablet and preparation method thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003436A1 (en) * | 1984-02-10 | 1985-08-15 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
US4713248A (en) * | 1984-02-10 | 1987-12-15 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
EP0277127A1 (en) * | 1985-10-11 | 1988-08-10 | Haessle Ab | New drug preparation with controlled release of the active compound, and a method for the manufacture thereof. |
EP0277874A2 (en) * | 1987-01-30 | 1988-08-10 | Elf Atochem S.A. | Composite copolymer, its preparation process and its use in the reinforcement of rigid thermoplastic matrices |
EP0305918A1 (en) * | 1987-09-03 | 1989-03-08 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
EP0361874A2 (en) * | 1988-09-27 | 1990-04-04 | Takeda Chemical Industries, Ltd. | Granules having core and their production |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
EP0447168A2 (en) * | 1990-03-16 | 1991-09-18 | Yamanouchi Pharmaceutical Co. Ltd. | Long acting granular pharmaceutical composition |
GB2241889A (en) * | 1990-03-15 | 1991-09-18 | Warner Lambert Co | Pharmaceutical controlled-release micropellets |
EP0452862B1 (en) * | 1990-04-18 | 1995-07-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Spherical seed cores, spherical granules and process for production thereof |
-
1994
- 1994-07-08 SE SE9402422A patent/SE9402422D0/en unknown
-
1995
- 1995-06-07 EE EE9600034A patent/EE03280B1/en unknown
- 1995-06-07 MX MX9600858A patent/MX9600858A/en unknown
- 1995-06-07 US US08/464,773 patent/US5783215A/en not_active Expired - Fee Related
- 1995-06-07 WO PCT/SE1995/000676 patent/WO1996001621A1/en not_active Application Discontinuation
- 1995-06-07 HU HU9600575A patent/HUT75772A/en unknown
- 1995-06-07 PL PL95313386A patent/PL313386A1/en unknown
- 1995-06-07 JP JP8504247A patent/JPH09502738A/en active Pending
- 1995-06-07 CN CN95190775A patent/CN1134108A/en active Pending
- 1995-06-07 NZ NZ289947A patent/NZ289947A/en unknown
- 1995-06-07 SK SK303-96A patent/SK30396A3/en unknown
- 1995-06-07 CZ CZ96731A patent/CZ73196A3/en unknown
- 1995-06-07 BR BR9506026A patent/BR9506026A/en not_active Application Discontinuation
- 1995-06-07 AU AU29936/95A patent/AU700949B2/en not_active Ceased
- 1995-06-07 RU RU96107106A patent/RU2141822C1/en active
- 1995-06-07 EP EP95926053A patent/EP0723434A1/en not_active Withdrawn
- 1995-06-07 CA CA002170526A patent/CA2170526A1/en not_active Abandoned
- 1995-06-15 TW TW084106118A patent/TW460300B/en active
- 1995-07-04 IL IL11444895A patent/IL114448A/en active IP Right Grant
- 1995-07-04 ZA ZA955545A patent/ZA955545B/en unknown
- 1995-07-06 TR TR95/00822A patent/TR199500822A2/en unknown
-
1996
- 1996-02-29 NO NO960837A patent/NO960837D0/en not_active Application Discontinuation
- 1996-03-07 FI FI961056A patent/FI961056A/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003436A1 (en) * | 1984-02-10 | 1985-08-15 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
US4713248A (en) * | 1984-02-10 | 1987-12-15 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
EP0277127A1 (en) * | 1985-10-11 | 1988-08-10 | Haessle Ab | New drug preparation with controlled release of the active compound, and a method for the manufacture thereof. |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
EP0475536A1 (en) * | 1987-01-29 | 1992-03-18 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
EP0277741B1 (en) * | 1987-01-29 | 1992-09-09 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
EP0277874A2 (en) * | 1987-01-30 | 1988-08-10 | Elf Atochem S.A. | Composite copolymer, its preparation process and its use in the reinforcement of rigid thermoplastic matrices |
EP0305918A1 (en) * | 1987-09-03 | 1989-03-08 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
EP0361874A2 (en) * | 1988-09-27 | 1990-04-04 | Takeda Chemical Industries, Ltd. | Granules having core and their production |
GB2241889A (en) * | 1990-03-15 | 1991-09-18 | Warner Lambert Co | Pharmaceutical controlled-release micropellets |
EP0447168A2 (en) * | 1990-03-16 | 1991-09-18 | Yamanouchi Pharmaceutical Co. Ltd. | Long acting granular pharmaceutical composition |
EP0452862B1 (en) * | 1990-04-18 | 1995-07-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Spherical seed cores, spherical granules and process for production thereof |
Non-Patent Citations (8)
Title |
---|
Abstract PDD 7397 from AAP s Congress, U.S.A., Pharmaceutical Research (Supplement), 1993. * |
Abstract PDD 7397 from AAP's Congress, U.S.A., Pharmaceutical Research (Supplement), 1993. |
Drug Development and Industrial Pharmacy, 18(18), 1927 1944 1992. * |
Drug Development and Industrial Pharmacy, 18(18), 1927-1944 1992. |
International Journal of Pharmaceutics, 103 (1994), 55 67. * |
International Journal of Pharmaceutics, 103 (1994), 55-67. |
International Journal of Pharmaceutics, 95 (1993), 29 42. * |
International Journal of Pharmaceutics, 95 (1993), 29-42. |
Cited By (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8329214B2 (en) | 1997-01-17 | 2012-12-11 | Laboratoires Fournier S.A. | Process for producing fenofibrate tablets |
US8343540B2 (en) | 1997-01-17 | 2013-01-01 | Laboratories Fournier S.A. | Process for producing fenofibrate tablets |
US20090035379A1 (en) * | 1997-01-17 | 2009-02-05 | Cabinet Hirsch | Fenofibrate compositions |
US20080063726A1 (en) * | 1997-01-17 | 2008-03-13 | Paul Royalty Fund Holdings Ii | Fenofibrate compositions |
US20040057999A1 (en) * | 1997-01-17 | 2004-03-25 | Andre Stamm | Fenofibrate compositions having enhanced bioavailability |
US20040057997A1 (en) * | 1997-01-17 | 2004-03-25 | Andre Stamm | Capsules containing fenofibrate compositions |
US20040057998A1 (en) * | 1997-01-17 | 2004-03-25 | Andre Stamm | Fenofibrate compositions |
US20040058004A1 (en) * | 1997-01-17 | 2004-03-25 | Andre Stamm | Suspensions of micronized fenofibrate |
US20080064759A1 (en) * | 1997-01-17 | 2008-03-13 | Paul Royalty Fund Holdings Ii | Process for preparing fenofibrate compositions |
US20040092597A1 (en) * | 1997-01-17 | 2004-05-13 | Andre Stamm | Fenofibrate compositions having high bioavailability |
US20070190136A1 (en) * | 1997-01-17 | 2007-08-16 | Laboratoires Fournier | Process for producing fenofibrate tablets |
US20070184103A1 (en) * | 1997-01-17 | 2007-08-09 | Laboratoires Fournier | Process for producing fenofibrate tablets |
US20060286163A1 (en) * | 1998-03-04 | 2006-12-21 | Thakur Madhav S | Pharmaceutical composition of topiramate |
US6805881B1 (en) * | 1998-09-18 | 2004-10-19 | Bayer Aktiengesellschaft | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same |
BG65149B1 (en) * | 1998-11-11 | 2007-04-30 | Pharmacia Ab | New controlled release bead, a method of producing the same and formulation comprising it |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US20030133982A1 (en) * | 2001-12-20 | 2003-07-17 | Heimlich John M. | Zero-order sustained release dosage forms and method of making same |
WO2003103637A2 (en) * | 2002-01-10 | 2003-12-18 | Ranbaxy Laboratories Limited | Modified release, multiple unit drug delivery systems |
US20060183779A1 (en) * | 2002-03-07 | 2006-08-17 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US9925174B2 (en) | 2002-03-07 | 2018-03-27 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
US7022342B2 (en) * | 2002-03-28 | 2006-04-04 | Andrx Corporation, Inc. | Controlled release oral dosage form of beta-adrenergic blocking agents |
US20060257482A1 (en) * | 2002-06-07 | 2006-11-16 | Patrik Kumar | Modified release, multiple unit drug delivery systems |
WO2003103637A3 (en) * | 2002-06-07 | 2004-05-13 | Ranbaxy Lab Ltd | Modified release, multiple unit drug delivery systems |
US7803402B2 (en) * | 2002-07-06 | 2010-09-28 | Sanjeev Khandelwal | Pharmaceutical preparations |
US20040005361A1 (en) * | 2002-07-06 | 2004-01-08 | Sanjeev Khandelwal | Pharmaceutical preparations |
US10646444B2 (en) | 2002-12-10 | 2020-05-12 | Nortec Development Associates, Inc. | Method of preparing biologically formulations active |
US20040185111A1 (en) * | 2002-12-10 | 2004-09-23 | Rubino Orapin P. | Method of preparing biologically active formulations |
US9107804B2 (en) | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
US10039717B2 (en) | 2002-12-10 | 2018-08-07 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
WO2004105735A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical compositions of tolterodine and processes for their preparation |
US9636306B2 (en) | 2003-06-26 | 2017-05-02 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US8603520B2 (en) | 2003-06-26 | 2013-12-10 | Intellipharmaceutics Corp. | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
US20080031946A1 (en) * | 2003-11-10 | 2008-02-07 | Ethypharm | Low-Dose Tablets Having a Network of Polymers |
NO338162B1 (en) * | 2003-11-10 | 2016-08-01 | Ethypharm Sa | Low dose tablets with a network of polymers |
FR2861990A1 (en) * | 2003-11-10 | 2005-05-13 | Nouveaux Produits Pharma | Low-dose tablets for oral administration are produced by direct compression of microgranules comprising an active ingredient layer on a release-modifying polymer layer on an inert support |
US8029825B2 (en) * | 2003-11-10 | 2011-10-04 | Ethypharm | Low-dose tablets having a network of polymers |
WO2005046647A1 (en) | 2003-11-10 | 2005-05-26 | Ethypharm | Low-dose tablets having a network of polymers |
USRE47084E1 (en) | 2003-11-25 | 2018-10-16 | Flamel Ireland Limited | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form |
EP1691789A2 (en) | 2003-11-25 | 2006-08-23 | SB Pharmco Puerto Rico Inc | Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
US20050175695A1 (en) * | 2003-11-25 | 2005-08-11 | Catherine Castan | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
US20070224269A1 (en) * | 2004-06-10 | 2007-09-27 | Rubino Orapin P | Controlled Release Pharmaceutical Formulation |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US20070202169A1 (en) * | 2005-12-20 | 2007-08-30 | Silver David I | Lansoprazole orally disintegrating tablets |
US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
US9943530B2 (en) | 2006-02-03 | 2018-04-17 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US11007204B2 (en) | 2006-02-03 | 2021-05-18 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US11911398B2 (en) | 2006-02-03 | 2024-02-27 | Opko Renal, Llc | Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US10213442B2 (en) | 2006-02-03 | 2019-02-26 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
US9561188B2 (en) | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
US20090068263A1 (en) * | 2006-04-20 | 2009-03-12 | Themis Laboratories Private Limited | Multiple unit compositions |
US20070248670A1 (en) * | 2006-04-21 | 2007-10-25 | Van Den Heuvel Dennie J M | Tolterodine beads |
US20070259041A1 (en) * | 2006-05-05 | 2007-11-08 | Wyeth | Solid dosage formulations |
US10632205B2 (en) | 2006-05-12 | 2020-04-28 | Intellipharmaceutics Corp | Pharmaceutical composition having reduced abuse potential |
US9078827B2 (en) | 2006-05-12 | 2015-07-14 | Isa Odidi | Pharmaceutical composition having reduced abuse potential |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US10668089B2 (en) | 2006-06-21 | 2020-06-02 | Opko Ireland Global Holdings, Ltd. | Method of treating and preventing secondary hyperparathyroidism |
US20090252787A1 (en) * | 2006-07-28 | 2009-10-08 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
US20110236475A1 (en) * | 2006-07-28 | 2011-09-29 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
US11154509B2 (en) | 2007-04-25 | 2021-10-26 | Eirgen Pharma Ltd. | Methods for controlled release oral dosage of a vitamin D compound |
US9918940B2 (en) | 2007-04-25 | 2018-03-20 | Opko Renal, Llc | Methods for controlled release oral dosage of a vitamin D compound |
US9498486B1 (en) | 2007-04-25 | 2016-11-22 | Opko Renal, Llc | Method for controlled release oral dosage of a vitamin D compound |
US9408858B2 (en) | 2007-04-25 | 2016-08-09 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in CKD |
US11801253B2 (en) | 2007-04-25 | 2023-10-31 | Opko Renal, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
US9925147B2 (en) | 2007-04-25 | 2018-03-27 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in CKD |
US20090017111A1 (en) * | 2007-07-03 | 2009-01-15 | Van Den Heuvel Dennie J M | Tolterodine bead |
US10302660B2 (en) | 2008-04-02 | 2019-05-28 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
US20110189280A1 (en) * | 2008-08-29 | 2011-08-04 | Allan James Clarke | Dosage form comprising 1-isopropyl-4-hexahydro-1h-1,4-diazepine or a salt thereof |
US9078830B2 (en) | 2009-07-31 | 2015-07-14 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
WO2011013082A1 (en) | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
US20140112995A1 (en) * | 2009-07-31 | 2014-04-24 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
AU2010277207B2 (en) * | 2009-07-31 | 2014-06-26 | Sun Pharmaceutical Industries Limited | Multi-layered, multiple unit pharmaceutical compositions |
WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
US9861644B2 (en) | 2013-03-15 | 2018-01-09 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US10357502B2 (en) | 2013-03-15 | 2019-07-23 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US11253528B2 (en) | 2013-03-15 | 2022-02-22 | Eirgen Pharma Ltd. | Stabilized modified release Vitamin D formulation and method of administering same |
US10350224B2 (en) | 2013-03-15 | 2019-07-16 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
US10300078B2 (en) | 2013-03-15 | 2019-05-28 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
EP2886110A1 (en) | 2013-12-23 | 2015-06-24 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
US11007205B2 (en) | 2014-08-07 | 2021-05-18 | Eirgen Pharma Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
US10493084B2 (en) | 2014-08-07 | 2019-12-03 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
US11738033B2 (en) | 2014-08-07 | 2023-08-29 | Eirgen Pharma Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
US11077055B2 (en) | 2015-04-29 | 2021-08-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US11166964B2 (en) | 2016-01-20 | 2021-11-09 | Galmed Research And Development Ltd | Treatment for modulating gut microbiota |
WO2017125929A1 (en) | 2016-01-20 | 2017-07-27 | Galmed Research And Development Ltd. | Treatment for modulating gut microbiota |
US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
US10835488B2 (en) | 2016-06-16 | 2020-11-17 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
Also Published As
Publication number | Publication date |
---|---|
JPH09502738A (en) | 1997-03-18 |
IL114448A (en) | 1999-09-22 |
AU2993695A (en) | 1996-02-09 |
BR9506026A (en) | 1997-10-14 |
MX9600858A (en) | 1997-06-28 |
NO960837L (en) | 1996-02-29 |
HUT75772A (en) | 1997-05-28 |
CN1134108A (en) | 1996-10-23 |
ZA955545B (en) | 1996-01-08 |
AU700949B2 (en) | 1999-01-14 |
IL114448A0 (en) | 1995-11-27 |
HU9600575D0 (en) | 1996-07-29 |
EE03280B1 (en) | 2000-08-15 |
SE9402422D0 (en) | 1994-07-08 |
WO1996001621A1 (en) | 1996-01-25 |
TW460300B (en) | 2001-10-21 |
PL313386A1 (en) | 1996-06-24 |
FI961056A (en) | 1996-05-06 |
NZ289947A (en) | 1998-07-28 |
EP0723434A1 (en) | 1996-07-31 |
NO960837D0 (en) | 1996-02-29 |
FI961056A0 (en) | 1996-03-07 |
RU2141822C1 (en) | 1999-11-27 |
SK30396A3 (en) | 1997-09-10 |
CZ73196A3 (en) | 1996-08-14 |
CA2170526A1 (en) | 1996-01-25 |
TR199500822A2 (en) | 1996-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5783215A (en) | Pharmaceutical preparation | |
AU623560B2 (en) | Pharmaceutical granules and drug dosage units made therefrom | |
AU2003231777C1 (en) | Pharmaceutical formulations with improved bioavailability | |
US6805881B1 (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
KR20110075011A (en) | Slow-release particle and a production method therefor | |
JPH0759500B2 (en) | Diffusion coated composite unit dose | |
JPH0759499B2 (en) | Diffusion coated composite unit dose | |
JP2005516020A (en) | Zero-order sustained release dosage form and process for its production | |
KR20090091084A (en) | Controlled-release pharmaceutical formulation | |
JP2008534531A (en) | Multiparticulate pharmaceutical dosage form with pellets having a matrix that affects the delivery of the modulator | |
CA2869054A1 (en) | Dosage forms of halofuginone and methods of use | |
US8642078B2 (en) | Coated formulations for tolterodine | |
WO2006045152A1 (en) | Improved tabletting process | |
US20080057118A1 (en) | Divalproex pharmaceutical compositions | |
WO1997025028A1 (en) | Pharmaceutical controlled release beads comprising furosemide and a formulation containing said controlled release beads | |
US20090136550A1 (en) | Modified release formulations of diltiazem | |
US8980318B2 (en) | Neramexane multiple unit dosage form | |
Torrado et al. | Tableting of multiparticulate modified release systems | |
MXPA99002404A (en) | Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2. 2]oct-3-yl)acetonitrile monohydrochloride | |
AU2005299253A1 (en) | Improved tabletting process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ASTRA AKTIEBOLAG, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARWIDSSON, HANS;STUBBERUD, LARS;REEL/FRAME:007675/0249 Effective date: 19950914 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100721 |